{
    "clinical_study": {
        "@rank": "13355", 
        "acronym": "VLX", 
        "arm_group": [
            {
                "arm_group_label": "venlafaxine", 
                "arm_group_type": "Experimental", 
                "description": "Venlafaxine IR and XR, single dosages of each separated by a wash-out period"
            }, 
            {
                "arm_group_label": "Venlafaxine XR and Venlafaxine IR", 
                "arm_group_type": "Other", 
                "description": "Each participant (3 groups of participants) will receive one dose of venlafaxine IR and one dose of venlafaxine XR seperated by a wash-out period."
            }
        ], 
        "brief_summary": {
            "textblock": "This study is being conducted to evaluate how the body absorbs and processes the immediate\n      release (IR) and sustained release (XR) medication venlafaxine (Effexor\u00ae). Subject who are\n      1-3 years post gastric bypass or sleeve gastrectomy surgery will be invited to participate.\n      Non-surgical controls will also be enrolled based on a matching criteria to post gastric\n      bypass subjects. Participants will be asked to complete two 12-hour study days approximately\n      11 days apart. This study will enroll up to 30 participants."
        }, 
        "brief_title": "Venlafaxine PK Following Bariatric Surgery", 
        "condition": [
            "Roux en Y Gastric Bypass", 
            "Sleeve Gastrectomy"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Male or Female\n\n          2. Age 18-65 (inclusive, at time of informed consent)\n\n          3. No tobacco use in the past three months.\n\n          4. Underwent Roux-en-Y Gastric Bypass or Sleeve Gastrectomy  weight loss surgery 12-36\n             months prior to study OR has not had a weight loss surgery but  matches the gastric\n             bypass patients on age, gender, and BMI.  Criteria for matching will be established\n             at the beginning of the study in consultation with the statistical team and addressed\n             as needed with the input of the biostatistician.\n\n          5. Ability to read, write and understand English\n\n        Exclusion Criteria:\n\n          1. Taking a medication that has a clinically significant interaction with venlafaxine or\n             an interaction that may alter the study data.\n\n          2. Hypersensitivity to venlafaxine or any excipient contained within the dosage forms\n\n          3. Inability to tolerate repeated blood draws.\n\n          4. Any history of bipoloar disorder or a psychotic disorder.\n\n          5. Current major depressive disorder or current suicidality.\n\n          6. Alcohol or substance dependence in the past year.\n\n          7. Currently pregnant or lactating or unwillingness to use medically accepted\n             contraception during study\n\n          8. Taking a medication which significantly alters gastrointesinal transit time or\n             significantly reduces acid secretion (e.g. routine use of proton pump inhibitors, H2\n             antagonists, sucralfate).\n\n          9. Medical conditon which may increase participant risk with venlafaxine or uncontrolled\n             hypertension at the discretion of the examining provider.\n\n         10. Hepatic insufficiency as defined by any hepatic enzyme greater than 3x the upper\n             limit of normal or other hepatic laboratory abnormalities at the discretion of the\n             medical provider.\n\n         11. Renal impairment as evidence by a calculated creatinine clearance of less than or\n             equal to 70ml/min or other abnormality on a renal panel that the medical provider\n             feels puts the participant at risk.\n\n         12. Poor or ultra-rapid Cytochrome P450 2D6 metabolizer.\n\n         13. Self reported history of viral hepatits or HIV.\n\n         14. Positive urine drug screen unless documented  prescription of a non-interacting\n             medication."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02005107", 
            "org_study_id": "KSteffenVLX", 
            "secondary_id": "EPSCOR"
        }, 
        "intervention": {
            "arm_group_label": [
                "venlafaxine", 
                "Venlafaxine XR and Venlafaxine IR"
            ], 
            "intervention_name": "Venlafaxine IR and Venlafaxine XR", 
            "intervention_type": "Drug", 
            "other_name": "Effexor and Effexor XR"
        }, 
        "intervention_browse": {
            "mesh_term": "Venlafaxine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 6, 2013", 
        "link": {
            "description": "Neuropsychiatric Research Institute Website", 
            "url": "http://www.nrifargo.com"
        }, 
        "location": [
            {
                "contact": {
                    "email": "rerickson@nrifargo.com", 
                    "last_name": "Ronald J Erickson", 
                    "phone": "701-293-1335"
                }, 
                "facility": {
                    "address": {
                        "city": "Fargo", 
                        "country": "United States", 
                        "state": "North Dakota", 
                        "zip": "58103"
                    }, 
                    "name": "Neuropsychiatric Research Institute"
                }, 
                "investigator": [
                    {
                        "last_name": "Kristine J Steffen, Pharm.D., Ph.D.", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "James E Mitchell, M.D.", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "James L Roerig, Pharm.D., BCPP", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Ross D Crosby, Ph.D.", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "rerickson@nrifargo.com", 
                    "last_name": "Ronald Erickson", 
                    "phone": "701-293-1335"
                }, 
                "contact_backup": {
                    "last_name": "James E Mitchell, M.D.", 
                    "phone": "701-293-1335"
                }, 
                "facility": {
                    "address": {
                        "city": "Fargo", 
                        "country": "United States", 
                        "state": "North Dakota", 
                        "zip": "58103"
                    }, 
                    "name": "Neuropsychiatric Research Institute"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Comparison of Immediate and Extended Release Venlafaxine Following Bariatric Surgery", 
        "overall_contact": {
            "email": "cnelson@nrifargo.com", 
            "last_name": "Carrie Nelson, BSN", 
            "phone": "701-630-1916"
        }, 
        "overall_official": {
            "affiliation": "North Dakota State University & Neuropsychiatric Research Institute", 
            "last_name": "Kristine J Steffen, Pharm.D., Ph.D.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary aim of this research is to provide a comparison of pharmacokinetic measures associated with a single dose of venlafaxine IR (immediate release) and venlafaxine XR (sustained release) in Roux-en-Y Gastric Bypass, Sleeve Gastrectomy, and matched nonsurgical \"control\" subjects. Comparisons will be based upon venlafaxine plasma concentrations obtained during the 24 hour sample collection window.", 
            "measure": "Venlafaxine Plasma Concentrations/Area-Under-the-Curve (AUC)", 
            "safety_issue": "No", 
            "time_frame": "24 hours intervals"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02005107"
        }, 
        "responsible_party": {
            "investigator_affiliation": "North Dakota State University", 
            "investigator_full_name": "Kristine Steffen", 
            "investigator_title": "Associate Professor, North Dakota State University", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "We will also evaluate other PK characteristics associated with venlafaxine, such as Cmax, Tmax, t1/2, and the ratio of venlafaxine to the active metabolite ODV, and others.", 
            "measure": "Secondary PK Characteristics (Composite)", 
            "safety_issue": "No", 
            "time_frame": "24 hour collection"
        }, 
        "source": "North Dakota State University", 
        "sponsors": {
            "collaborator": {
                "agency": "Neuropsychiatric Research Institute", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "North Dakota State University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}